Felix operates a digital-first, end-to-end platform that connects Canadians with healthcare practitioners via text, audio, and video and delivers prescriptions and tests discreetly to patients’ doors. The company treats conditions including erectile dysfunction, weight loss, hair loss, HIV prevention, acne, and birth control and supports ongoing follow-ups. Launched in 2019, Felix says it is Canada’s first end-to-end on-demand treatment platform and emphasizes accessibility for patients who lack timely in-person care. Felix plans to expand into new, more complex care categories and launch additional therapeutic services in 2023, backed by investments in technology, operations, and its team. Financially, Felix completed a Series B raise of CDN $18 million to accelerate growth. Operational metrics in the article cite over 540,000 registered users, more than 200% year-over-year growth since launch, and that 40% of patients are seeking an initial prescription for their health concern. Felix has launched a digital health platform that lets users request diagnoses via an online quiz, have a licensed Canadian doctor review their medical history and symptoms, and chat through a secure messaging system. Doctors can issue prescriptions that are filled and shipped by an accredited pharmacy with discreet packaging and an option for recurring delivery, typically within two days. The platform does not require appointments and does not rely exclusively on phone or video consultations. Current treatment areas include birth control, hair loss, and acne, with planned expansion into aging, wrinkles, cold sores, herpes, HIV prevention, HSDD, and smoking cessation. The company raised $750,000 in a seed financing in March to hire key staff, enhance the platform, and expand services across Canada. Felix is positioning the raise as a bridge to a Series A targeted for the second half of its 2019 fiscal year.

Total raised

$14M

Funding rounds

2

Latest round

Series B

Latest activity

Apr 2023